Agensys' Unattributed VC Round

Agensys raised a round of funding on March 22, 2002.

Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validat…

Articles about Agensys' Unattributed VC Round: